Marker Therapeutics (MRKR) Other financing activities (2010 - 2026)
Marker Therapeutics (MRKR) reported Other financing activities of $178422.0 for Q1 2026, down 52.94% year-over-year from $379144.0 in Q1 2025, and up 60.55% quarter-over-quarter from $111131.0 in Q4 2025.
Marker Therapeutics (MRKR) Other financing activities (2010 - 2026) Analysis & Trends
Marker Therapeutics (MRKR) has 13 years of Other financing activities data on file, last reported at $178422.0 in Q1 2026.
- Other financing activities for Q1 2026 came in at $178422.0, down 52.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $336818.0 (down 38.27% YoY), and the FY2025 annual result was $537540.0, up 118.63% from the prior year.
- Other financing activities grew to $178422.0 in Q1 2026 per MRKR's latest filing, from $111131.0 in the prior quarter.
- Over five years, Other financing activities peaked at $1.6 million in Q1 2022 and troughed at $13986.0 in Q2 2025.
- A 5-year average of $464060.9 and a median of $175041.0 in 2023 frame the typical range for Other financing activities.
- The sharpest annual moves came in 2024 and 2025: Other financing activities sank 89.65% in 2024, then jumped 377.41% in 2025.
- A 5-year view of Other financing activities shows it stood at $717173.0 in 2022, then sank by 80.01% to $143370.0 in 2023, then plunged by 64.75% to $50544.0 in 2024, then jumped by 119.87% to $111131.0 in 2025, then jumped by 60.55% to $178422.0 in 2026.
- Business Quant data shows MRKR's Other financing activities at $178422.0 in Q1 2026, $111131.0 in Q4 2025, and $33279.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Marker Therapeutics | 28.20 Mn | 28.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 178,422.00 |
| Mar 31, 2026 | 178,422.00 |
| Dec 31, 2025 | 111,131.00 |
| Dec 31, 2025 | 111,131.00 |
| Sep 30, 2025 | 33,279.00 |
| Sep 30, 2025 | 33,279.00 |
| Jun 30, 2025 | 13,986.00 |
| Jun 30, 2025 | 13,986.00 |
| Mar 31, 2025 | 379,144.00 |
| Mar 31, 2025 | 379,144.00 |
| Dec 31, 2024 | 50,544.00 |
| Dec 31, 2024 | 50,544.00 |
| Sep 30, 2024 | 53,302.00 |
| Sep 30, 2024 | 53,302.00 |
| Jun 30, 2024 | 62,601.00 |
| Jun 30, 2024 | 62,601.00 |
| Mar 31, 2024 | 79,417.00 |
| Mar 31, 2024 | 79,417.00 |
| Dec 31, 2023 | 143,370.00 |
| Dec 31, 2023 | 143,370.00 |